LIVN

LivaNova PLC

$91.14

-1.59%
SectorHealthcareIndustryMedical DevicesCountryUnited Kingdom

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea.

Source: Yahoo Finance
AI summary

Price & performance

1M+19.2%
3M+16.6%
YTD+50.3%
1Y+79.4%
52-week range—
Beta0.99
Full chart and returns against a benchmark

Q-Score

70/ 100

Quality against peers; 50 is the peer median.

Growth59
Risk73
Performance62
Valuation60
Profitability68
Leverage58
Sentiment72
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$1.4B+10.7%
Net income-$242.5M-483.5%
Net margin-17.5%-22.5 pts
Historical fundamentals

Revenue exposure

47%of revenue from outside the US
United States53%
Locations Excluding The United States And Europe27%
Europe19%
Regions, segments, customers and suppliers

Valuation

LIVNIndustryP/E25.6129.61P/S3.333.49EV/EBITDA24.2918.38P/B3.663.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report, before the open
EPS estimate$1.06
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate